Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous
15 Sep 2022
ESMO Congress 2022. Winette van der Graaf, president of EORTC, talks about the importance and challenges of placing the patient at the center of clinical trials. She states that patients are usually highly motivated to participate in clinical trials. However, several challenges, such as logistics, communication issues, and geographic distance to a trial center, may prevent them from doing so. Moreover, the current strict enrolment criteria often exclude older patients from clinical trials. The result is that trials tend to be overly homogeneous, thus limiting the generalisability of the data. With an aging population, we need more elderly patients to participate in clinical trials. Read the full article here.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023